Delivery included to the United States

Novel Developments in Stem Cell Mobilization

Novel Developments in Stem Cell Mobilization Focus on CXCR4

2012

Paperback (12 Apr 2014)

  • $189.89
Add to basket

Includes delivery to the United States

10+ copies available online - Usually dispatched within 7 days

Publisher's Synopsis

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.

Book information

ISBN: 9781489993762
Publisher: Springer New York
Imprint: Springer
Pub date:
Edition: 2012
Language: English
Number of pages: 498
Weight: 777g
Height: 235mm
Width: 155mm
Spine width: 28mm